Shares of aTyr Pharma, Inc. (NASDAQ:LIFE) traded up 19.1% during mid-day trading on Friday . The stock traded as high as $0.97 and last traded at $1.12. 189,107 shares were traded during trading, a decline of 71% from the average session volume of 645,140 shares. The stock had previously closed at $0.94.
Several analysts have issued reports on the company. Zacks Investment Research cut aTyr Pharma from a “buy” rating to a “hold” rating in a research note on Friday, March 30th. Piper Jaffray Companies restated an “overweight” rating and set a $3.00 price objective on shares of aTyr Pharma in a research note on Monday, May 14th. ValuEngine upgraded aTyr Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. Citigroup cut aTyr Pharma from a “neutral” rating to a “sell” rating in a research note on Monday, May 14th. Finally, JPMorgan Chase & Co. cut aTyr Pharma from a “neutral” rating to an “underweight” rating in a research note on Wednesday, February 14th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. aTyr Pharma currently has a consensus rating of “Hold” and a consensus price target of $3.33.
Get aTyr Pharma alerts:
The firm has a market cap of $25.20 million, a P/E ratio of -0.55 and a beta of 3.20. The company has a quick ratio of 6.90, a current ratio of 6.90 and a debt-to-equity ratio of 0.24.
aTyr Pharma (NASDAQ:LIFE) last posted its earnings results on Monday, March 19th. The biotechnology company reported ($0.39) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.04. sell-side analysts predict that aTyr Pharma, Inc. will post -1.18 EPS for the current fiscal year.
In other news, major shareholder Ecor1 Capital Fund Qualified, sold 3,209,316 shares of the company’s stock in a transaction that occurred on Wednesday, May 16th. The stock was sold at an average price of $0.93, for a total transaction of $2,984,663.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Paul Schimmel bought 150,000 shares of the stock in a transaction dated Friday, May 18th. The shares were bought at an average cost of $1.00 per share, with a total value of $150,000.00. The disclosure for this purchase can be found here. 25.00% of the stock is currently owned by corporate insiders.
Several large investors have recently bought and sold shares of the company. Sofinnova Ventures Inc bought a new position in shares of aTyr Pharma during the first quarter valued at approximately $4,945,000. Dimensional Fund Advisors LP grew its holdings in shares of aTyr Pharma by 33.5% during the first quarter. Dimensional Fund Advisors LP now owns 114,449 shares of the biotechnology company’s stock valued at $303,000 after purchasing an additional 28,699 shares during the last quarter. Deutsche Bank AG bought a new position in shares of aTyr Pharma during the fourth quarter valued at approximately $199,000. Renaissance Technologies LLC grew its holdings in aTyr Pharma by 143.2% in the 4th quarter. Renaissance Technologies LLC now owns 279,400 shares of the biotechnology company’s stock worth $978,000 after buying an additional 164,500 shares in the last quarter. Finally, Artal Group S.A. grew its holdings in aTyr Pharma by 100.0% in the 4th quarter. Artal Group S.A. now owns 500,000 shares of the biotechnology company’s stock worth $1,750,000 after buying an additional 250,000 shares in the last quarter. 64.59% of the stock is owned by institutional investors.
aTyr Pharma Company Profile
aTyr Pharma, Inc, a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings.
